Medical University of Silesian

Zabrze, Poland

Medical University of Silesian

Zabrze, Poland
SEARCH FILTERS
Time filter
Source Type

Ahmedzai S.H.,University of Sheffield | Leppert W.,Poznan University of Medical Sciences | Janecki M.,Medical University of Silesian | Pakosz A.,God's Mercy Hospice | And 3 more authors.
Supportive Care in Cancer | Year: 2014

Aim: To evaluate the long-term safety and efficacy of prolonged-release oxycodone/naloxone (OXN PR) and its impact on quality of life (QoL), in patients with moderate-to-severe cancer pain.Methods: This was an open-label extension (OLE) of a 4 week, randomized, double-blind (DB) study in which patients with moderate-to-severe cancer pain had been randomized to OXN PR or oxycodone PR (OxyPR). During the OLE phase, patients were treated with OXN PR capsules (≤20/60 mg/day) for ≤24 weeks. Outcome measures included safety, efficacy and QoL.Results: One hundred and twenty-eight patients entered the OLE, average pain scores based on the modified Brief Pain Inventory—Short Form were low and stable over the 24-week period. The improvement in bowel function and constipation symptoms as measured by the Bowel Function Index and patient assessment of constipation in patients treated with OXN PR during the 4-week DB study was maintained. In patients treated with OxyPR during the DB phase, bowel function and constipation symptoms were improved during the OLE. In the DB and in the OLE, health status and QoL were similar for patients treated with OXN PR and OxyPR. There were no unexpected safety or tolerability issues.Conclusions: In patients with moderate-to-severe cancer pain, long-term use of OXN PR is well tolerated and effective, resulting in sustained analgesia, improved bowel function and improved symptoms of constipation. © 2014, The Author(s).


Kuter K.,Polish Academy of Sciences | Nowak P.,Medical University of Silesian | Golembiowska K.,Polish Academy of Sciences | Ossowska K.,Polish Academy of Sciences
Neurochemical Research | Year: 2010

The pesticide paraquat (PQ) was found to be a suitable xenobiotic to model Parkinson's disease. The reactive oxygen species (ROS) production was suggested to be the main cause of PQ toxicity but very few evidences were found for its generation in the brain in vivo after ip administration. We compared the effects of PQ-induced ROS generation between the brain structures and the peripheral tissues using two different hydroxyl radical generation markers. Repeated but not single ip PQ administration increased the levels of ROS in the striatal homogenates but, when measured in the extracellular microdialysis filtrate, no change was observed. The increased dopamine release was detected in the striatum after the fourth PQ administration and its basal levels were decreased. A single treatment with the pesticide did not influence ROS production in the lungs or kidneys but repeated intoxication decreased its levels. These results suggest that repeated, systemic administration of a low dose of PQ triggers intracellular ROS formation in the brain and can cause slowly progressing degenerative processes, without the toxic effects in the peripheral tissues. © 2010 Springer Science+Business Media, LLC.

Loading Medical University of Silesian collaborators
Loading Medical University of Silesian collaborators